Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
Hybridoma Technology01:31

Hybridoma Technology

14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

88
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
88
Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standard Methods for Quality Control in Cell-Based Medicinal Products and their Validation for Clinical Applications.

Advanced biomedical research·2026
Same author

Determinants of MSC immunophenotypic plasticity: From canonical priming to emerging strategies for cancer and inflammatory therapies.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Impact of stem cell therapy on brain metabolic profile in cerebral palsy assessed by magnetic resonance spectroscopy in a randomized clinical trial.

Scientific reports·2026
Same author

Targeting PCSK9, APOB, and CETP at the Transcriptome Level by hsa-miR-30b-3p Reduces LDL-Associated Protein in Huh-7 Cells.

Molecular biology reports·2026
Same author

Mechanical signature of cancer cells: From cytoskeletal alterations to cell rheology.

Progress in biophysics and molecular biology·2026
Same author

Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver-bone model.

Archives of toxicology·2026

Related Experiment Video

Updated: Jun 5, 2025

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.7K

Developing a multi-epitope vaccine against Helicobacter Pylori.

Pedram Asadi Sarabi1, Elham Rismani2, Mahshid Shabanpouremam3

  • 1Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.

Human Immunology
|December 6, 2024
PubMed
Summary

This study presents a novel computational vaccine design against Helicobacter pylori, a bacterium linked to gastric cancer. The proposed vaccine targets key antigens and shows promising immunogenicity and stability for future development.

Keywords:
Helicobacter pyloriImmunoinformaticsMulti-epitope vaccineTherapeutic immunization

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
00:10

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.5K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

281

Related Experiment Videos

Last Updated: Jun 5, 2025

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.7K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
00:10

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.5K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

281

Area of Science:

  • * Computational vaccinology and bioinformatics
  • * Infectious disease research and immunology
  • * Molecular modeling and drug design

Background:

  • * Helicobacter pylori infection is a major cause of gastric cancer and peptic ulcers.
  • * The bacterium's resilience presents significant challenges for traditional drug development.
  • * Novel therapeutic strategies, including vaccines, are needed to combat H. pylori.

Purpose of the Study:

  • * To design a stable and immunogenic vaccine against H. pylori using computational methods.
  • * To identify critical antigenic proteins for vaccine development.
  • * To assess the vaccine's potential efficacy and safety through in silico analysis.

Main Methods:

  • * Selection of four key antigenic proteins: HpaA, KatA, UreB, and VacA.
  • * Application of immunoinformatics for predicting immunological response.
  • * Fusion of 50S ribosomal protein L7/L12 as an adjuvant.
  • * Molecular dynamics simulations using GROMACS and OPLS-AA force field.
  • * In silico cloning into the pET28b (+) expression vector.
  • * Docking studies with human Toll-like receptor 5 (TLR5).
  • * Immune response simulation modeling.

Main Results:

  • * Identified four critical antigenic proteins for vaccine formulation.
  • * Enhanced vaccine immunogenicity through adjuvant fusion and structural optimization.
  • * Demonstrated strong binding affinity between the vaccine and TLR5.
  • * In silico simulations predicted significant vaccine efficacy and immune system modulation.
  • * Successfully cloned the vaccine candidate in silico using pET28b (+) vector.

Conclusions:

  • * The developed computational vaccine design shows high potential for combating H. pylori infections.
  • * The vaccine's stability, immunogenicity, and predicted efficacy warrant further experimental validation.
  • * This in silico approach provides a foundation for developing a novel H. pylori vaccine.